329203-85-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-4-((triMethylsilyl)ethynyl)thiazole is used as an intermediate in the synthesis of MTEP Hydrochloride (M759900), a potent mGlu5 receptor antagonist. It acts as a negative allosteric modulator, which means it can bind to the mGlu5 receptor and alter its function without directly activating it. This property makes it a valuable compound in the development of drugs targeting the mGlu5 receptor, which is involved in various neurological and psychiatric disorders.
2-Methyl-4-((triMethylsilyl)ethynyl)thiazole's role as an intermediate in the synthesis of MTEP Hydrochloride highlights its importance in the pharmaceutical industry, particularly in the development of treatments for conditions such as anxiety, schizophrenia, and chronic pain. By modulating the mGlu5 receptor, MTEP Hydrochloride has the potential to provide therapeutic benefits for patients suffering from these disorders.

Upstream product

• 18245-82-4 1-chloro-4-(trimethylsilyl)but-3-yn-2-one 
• 62-55-5 thioacetamide 
• 79-04-9 chloroacetyl chloride 
• 14630-40-1 Bis(trimethylsilyl)ethyne 
• 1066-54-2 trimethylsilylacetylene 
• 298694-30-1 4-bromo-2-methyl-1,3-thiazole 

Downstream Products

• 329205-68-7 3-[(2-methyl-4-thiazolyl)ethynyl]pyridine 
• 686768-53-6 3-(2-(2-methylthiazol-4-yl)ethynyl)-5-bromobenzonitrile 
• 1160219-19-1 2-fluoro-1-(methoxymethoxy)-4-(2-methylthiazol-4-ylethynyl)benzene 
• 1160219-17-9 3-(2-(2-methylthiazol-4-yl)ethynyl)-5-bromofluorobenzene 
• 1384843-64-4 C₁₄H₁₁NOS 
• 1384843-65-5 C₁₄H₁₃NOS 
• 1384843-67-7 C₁₄H₁₁NO₂S 
• 1384843-68-8 C₁₆H₁₅NO₂S 

Relevant academic research and scientific papers

NOVEL GALACTOSIDE INHIBITOR OF GALECTINS

The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of inflammation; Inflammation induced thrombosis; Atopic dermatitis; Acute coronary syndrome; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart; local fibrosis such as Dupuytren's disease and Peyronie's disease; fibrotic complications of other therapies such as coronary stents, bile duct stents, cerebral artery stents, ureter stents; scleroderma; scarring; keloid formation; covid-19; acute lung injury; ARDS; viral pneumonitis, aberrant scar formation; surgical adhesions; septic shock; cancer, such as colorectal cancer, other gastrointestinal carcinomas such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancers, mesothelioma, female cancers like breast cancer, ovarian cancer, uterine cancer, cancer of the cervix uteri, cancer of the salpingx, cerebral cancers such as medulloblastomao, glioma, meningioma, sarcomas of the bones and muscles and other sarcomas, leukemias and lymphomas, such as T-cell lymphomas; transplant rejection; metastasising cancers; ageing; Dementia; Alzheimers; TGFbeta driven bone disease such as osteogenesis imperfecta; Pulmonary hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Rheumatoid lung; Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, Herpes virus, Coronaviruses, Hepatitis C; metabolic disorders; heart disease; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistens; obesity; Marfans syndrome; Loeys–Dietz syndrome; nephropathy; Diastolic HF; fibrotic lung complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, liver disorders, such as non- alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine disease such as uterine fibroids and uterine or cervical fibrosis.

Synthesis toward Bivalent Ligands for the Dopamine D2 and Metabotropic Glutamate 5 Receptors

In this study, we designed and synthesized heterobivalent ligands targeting heteromers consisting of the metabotropic glutamate 5 receptor (mGluR5) and the dopamine D2 receptor (D2R). Bivalent ligand 22a with a linker consisting of 2

Enhanced copper-mediated 18F-fluorination of aryl boronic esters provides eight radiotracers for PET applications

[18F]FMTEB, [18F]FPEB, [18F]flumazenil, [18F]DAA1106, [18F]MFBG, [18F]FDOPA, [18F]FMT and [18F]FDA are prepared from the corresponding arylboronic esters and [18

Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: Discovery and computational modeling of a new series of ligands with nanomolar affinity

Abstract Metabotropic glutamate receptor 5 (mGlu5) is a biological target implicated in major neurological and psychiatric disorders. In the present study, we have investigated structural determinants of the interaction of negative allosteric m

Catalysis by zeolite leading to the construction of thiazole ring: An improved synthesis of 4-alkynyl substituted thiazoles

Zeolite H-beta facilitated the reaction of α-chloro acetyl chloride with 1,2-bis-trimethyl silyl acetylene to give 1-chloro-4-(trimethylsilyl)but-3- yn-2-one which on treatment with thioacetamide afforded 2-methyl-4- [(trimethylsilyl)ethynyl]thiazole. l-P

OXAZOLIDINONES AS MODULATORS OF MGLUR5

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.

Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol- 4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications

Recent genetic and pharmacological studies have suggested that the metabotropic glutamate receptor subtype 5 (mGluR5) may represent a druggable target in identifying new therapeutics for the treatment of various central nervous system disorders including drug abuse. In particular, considerable attention in the mGluR5 field has been devoted to identifying ligands that bind to the allosteric modulatory site, distinct from the site for the primary agonist glutamate. Both 2-methyl-6-(phenylethynyl)pyridine (MPEP) and its analogue 3-[(2-methyl-4-thiazolyl)ethynyl]pyridine (MTEP) have been shown to be selective and potent noncompetitive antagonists of mGluR5. Because of results presented in this study showing that MTEP prevents the reinstatement of cocaine self-administration caused by the presentation of environmental cues previously associated with cocaine availability, we have prepared a series of analogues of MTEP with the aim of gaining a better understanding of the structural features relevant to its antagonist potency and with the ultimate aim of investigating the effects of such compounds in blunting the self-administration of cocaine. These efforts have led to the identification of compounds showing higher potency as mGluR5 antagonists than either MPEP or MTEP. Two compounds 19 and 59 exhibited functional activity as mGluR5 antagonists that are 490 and 230 times, respectively, better than that of MTEP.

3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity

2-Methyl-6-(phenylethynyl)pyridine (3), a potent noncompetitive mGlu5 receptor antagonist widely used to characterize the pharmacology of mGlu5 receptors, suffers from a number of shortcomings as a therapeutic agent, including off-target activity and poor